Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Availability Heuristic

The Availability Heuristic

A heuristic is a general problem-solving framework (Tversky & Kahneman, 1974). You can think of these as mental shortcuts that are used to solve problems. Different types of heuristics are used in different types of situations, and the impulse to use a heuristic occurs when one of five conditions is met (Pratkanis, 1989):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities.

Molecular therapy. Oncology·2026

Same author

Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior <i>in vivo</i> T cell history.

Molecular therapy. Methods & clinical development·2025

Same author

Trifluridine- and tipiracil-induced DPD inhibition mimicking DPD deficiency: a case report.

Frontiers in oncology·2025

Same author

Impact of gastrectomy on cabozantinib exposure: Clinical case of a patient with clear renal cell carcinoma.

Clinical genitourinary cancer·2025

Same author

Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.

Cancer chemotherapy and pharmacology·2024

Same author

Large-Scale DPD Testing Should Be More Than an Option.

JCO oncology practice·2024

Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026

Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026

Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026

Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026

Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026

Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

[Not Available].

Pauline Gerritsen-van Schieveen¹, Bernard Royer²,

¹CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France.

|July 10, 2016

Summary

This summary is machine-generated.

Therapeutic drug monitoring of mycophenolic acid (MPA) aids in preventing Graft Versus Host Disease (GVHD) after stem cell transplants. Defining the best pharmacokinetic parameter, like total MPA, is crucial for effective monitoring in reduce-intensity conditioning regimens.

Keywords:

MPA acide mycophénolique conditionnement atténué greffe de cellules souches hematopoietic stem cells level of evidence niveau de preuve transplantation reduced-intensity conditioning

More Related Videos

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Related Experiment Videos

Last Updated: Mar 18, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Area of Science:

Pharmacology
Immunology
Hematology

Context:

Mycophenolic acid (MPA) is increasingly utilized for Graft Versus Host Disease (GVHD) prophylaxis in hematopoietic stem cell transplantation (HSCT) using reduce-intensity conditioning.
The need for therapeutic drug monitoring (TDM) of MPA is supported by growing evidence.
Optimal pharmacokinetic parameters for MPA TDM in this context require further definition.

Purpose:

To evaluate the evidence supporting the use of MPA for GVHD prophylaxis in HSCT with reduce-intensity conditioning.
To discuss the choice of pharmacokinetic parameters for MPA TDM, specifically total versus ultrafilterable MPA.
To highlight the need for further studies assessing MPA TDM and other factors influencing GVHD.

Summary:

MPA is a key agent for preventing GVHD in HSCT, but TDM is essential for optimizing its use.
The debate continues regarding whether total or ultrafilterable MPA is the superior pharmacokinetic parameter for TDM, though total MPA appears more practical.
Further research is needed to clarify the role of MPA TDM and other contributing factors in GVHD occurrence.

Impact:

This review provides a comprehensive overview of the current evidence for MPA in GVHD prophylaxis.
It guides clinicians in selecting appropriate pharmacokinetic parameters for MPA TDM, potentially improving patient outcomes.
Identifies research gaps and future directions for optimizing MPA-based GVHD prevention strategies in HSCT.